| Outcome Measures: |
Primary: Hepatic de novo lipogenesis (DNL) (absolute value), Percent incorporation of newly synthesized fatty acids into plasma or VLDL TG. During both inpatient (overnight) study visits, starting after investigational agent dose. units: %, Up to 24 hours after dosing|Hepatic de novo lipogenesis (DNL) (relative value), Percent incorporation of newly synthesized fatty acids into plasma or VLDL TG. During both inpatient (overnight) study visits, starting after investigational agent dose. unit: fold difference and/or ∆% versus other group, Up to 24 hours after dosing|Endogenous glucose production (EGP) (absolute value), Calculated from D2G tracer enrichment by the Steele equations. During both inpatient (overnight) study visits, starting after investigational agent dose. units: mg/kg/min, Up to 15 hours after dosing|Endogenous glucose production (EGP) (relative value), Calculated from D2G tracer enrichment by the Steele equations. During both inpatient (overnight) study visits, starting after investigational agent dose. units: fold difference and/or ∆% versus other group, Up to 15 hours after dosing | Secondary: Serum insulin level, Serum insulin levels in response to placebo vs alpelisib following an overnight fast and then hourly during refeeding. During Study Day 2 of both study visits, starting after investigational agent dose. units: µIU/mL, Approximately 11-19 hours after dosing|Plasma glucose level, Plasma glucose levels in response to placebo vs alpelisib following an overnight fast and then hourly during refeeding. During Study Day 2 of both study visits, starting after investigational agent dose. units: mg/dL, Approximately 11-19 hours after dosing|Triglycerides level, (Serum or plasma) triglyceride levels in response to placebo vs alpelisib following an overnight fast and then hourly during refeeding. During Study Day 2 of both study visits, starting after investigational agent dose. units: mg/dL, Approximately 11-19 hours after dosing|Free fatty acids level, (Serum or plasma) triglyceride levels in response to placebo vs alpelisib following an overnight fast and then periodically during refeeding. During Study Day 2 of both study visits, starting after investigational agent dose. units: mmol/L, Approximately 11-19 hours after dosing|Glucose kinetics: rate of appearance (absolute value), Calculated from D2G tracer enrichment by the Steele equations. During both inpatient (overnight) study visits, starting after investigational agent dose. units: mg/kg/min, Up to 15 hours after dosing|Glucose kinetics: rate of appearance (relative value), Calculated from D2G tracer enrichment by the Steele equations. During both inpatient (overnight) study visits, starting after investigational agent dose. units: fold difference and/or ∆% versus other group, Up to 15 hours after dosing|Glucose kinetics: rate of disappearance (absolute value), Calculated from D2G tracer enrichment by the Steele equations. During both inpatient (overnight) study visits, starting after investigational agent dose. units: mg/kg/min, Up to 15 hours after dosing|Glucose kinetics: rate of disappearance (relative value), Calculated from D2G tracer enrichment by the Steele equations. During both inpatient (overnight) study visits, starting after investigational agent dose. units: fold difference and/or ∆% versus other group, Up to 15 hours after dosing
|
